Hungary

Archived Projects: 7

Project Investigator All Locations Start date End date
Centre of Excellence in Nurses and Tobacco Control in Eastern Europe Stella Bialous, RN, DrPH Czech Republic, Hungary, Romania, Slovakia, Slovenia
Office of the UN Special Envoy for Tuberculosis Eric Goosby, MD Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Central Asia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, South Korea, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Caribbean, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, United States, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C Anne F. Luetkemeyer, MD France, Germany, Hungary, Spain, Argentina
Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder R. Keith McBurnett, PhD Germany, Hungary, Italy, Romania, Spain, Sweden, Mexico, Canada
WHO Adolescent HTC Review Update (PO# 200660799) George W. Rutherford, MD Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Western Africa, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, Japan, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka, Brunei, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
Congenital Syphilis Elimination Cost-Effectiveness Analysis James G. Kahn, MD, MPH Burundi, Comoros, Djibouti, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Tanzania, Zambia, Zimbabwe, Cameroon, Central African Republic, Chad, Congo (Brazzaville), Gabon, Sao Tome and Principe, Sudan, Tunisia, Botswana, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Ivory Coast, Ghana, Guinea, Mali, Nigeria, Sierra Leone, Togo, Kazakhstan, Kyrgyzstan, Uzbekistan, China, Mongolia, Afghanistan, Bangladesh, India, Maldives, Nepal, Sri Lanka, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Thailand, Philippines, Jordan, Oman, Saudi Arabia, Belarus, Czech Republic, Estonia, Germany, Hungary, Lithuania, Macedonia, Moldova, Romania, United Kingdom, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Uruguay, Antigua and Barbuda, Cuba, Dominica, Dominican Republic, Grenada, Trinidad and Tobago, Fiji, Kiribati, Papua New Guinea
Recommendations for Future Studies of Air Pollution and Adverse Perinatal Outcomes Tracey Woodruff, PhD, MPH China, Indonesia, Viet Nam, Malaysia, Austria, Denmark, France, Greece, Hungary, Netherlands, Norway, Sweden, United Kingdom

Active Investigators: 1